Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
An investigation finds that dozens of academic titles offered 'Dr Fraud' — a sham, unqualified scientist — a place on their editorial board. Katarzyna Pisanski and colleagues report.
Masoud Mohseni, Peter Read, Hartmut Neven and colleagues at Google's Quantum AI Laboratory set out investment opportunities on the road to the ultimate quantum machines.
Jeffrey S. Mogil and Malcolm R. Macleod propose a new kind of paper that combines the flexibility of basic research with the rigour of clinical trials.
A newly unearthed article by the great politician reveals that he reasoned like a scientist about the likelihood of extraterrestrials, writes Mario Livio.
Ethical review boards must focus on clinical promise as well as safety to hold the first tests of drugs in humans to a higher standard, say Jonathan Kimmelman and Carole Federico.
Police agencies, software firms and the public must ensure that crime-forecasting software improves public safety and officer accountability, writes Aaron Shapiro.
Erica Ollmann Saphire and colleagues share lessons in finding treatments fast from the work on Ebola by the Viral Hemorrhagic Fever Immunotherapeutic Consortium.
Gary McDowell, Misty Heggeness and colleagues present census data showing how the biomedical workforce is fundamentally different to those of past generations – academia should study the trends, and adapt.